JPRN-UMIN000010685招募中2 期
Phase II study of EC followed by Nab-paclitaxel as neoadjuvant chemotherapy for HER2 negative with lymph node metastases - Phase II study of EC followed by Nab-paclitaxel as neoadjuvant chemotherapy for HER2 negative with lymph node metastases
Saitama Medical Center,Saitama Medical University0 个研究点目标入组 40 人开始时间: 2013年5月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)History of hypersensitivity reaction 2)Active another cancer 3)Other severe complications, such as uncontrolled diabetes mellitus, uncontrolled angina, myocardial infarction within 6 months, heart failure. 4)Severe mental disorder 5)Sever bone marrow suppression, renal dysfunction, liver dysfunction 6)Body cavity fluid 7)Active infection or potentiality infection 8)Pregnant or lactating women, women who are capable of pregnancy, intend to get pregnant 9)Judged ineligible based on physicians' decision
研究者
相似试验
已完成
2 期
Phase II study of EC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Early Breast Cancerbreast cancerJPRN-UMIN000006020Tokai University School of Medicine50
已完成
2 期
PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancerBreast cancerJPRN-UMIN000022931Rakuwakai Otowa Hospital Breast oncology department24
招募中
2 期
A Phase II trial of nab-paclitaxel followed by EC as neoadjuvant chemotherapy for resectable breast cancer.breast cancerJPRN-UMIN000017382Tokyo Women's Medical University,Department of endocrine surgery36
已完成
2 期
Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancerbreast cancerJPRN-UMIN000011048Kitasato University Kitasato Institute Hospital20
招募中
2 期
Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancerbreast cancerJPRN-UMIN000006428Toho University Omori Medical Center40